Quatre Lab, backed by Columbus Venture Partners and Grupo SPRI, establishes itself in the Gipuzkoa Science and Technology Park

QUATRE LAB, a new company aiming to establish itself as a leader in the field of Quality Control analysis for advanced therapies, announces the opening of its facilities in the Gipuzkoa Science and Technology Park.

QUATRE LAB positions itself as a reference point in the pharmaceutical and biotechnological sectors, offering specialized services in the evaluation and certification of Advanced Therapy Medicinal Products for companies and entities seeking to ensure the quality and effectiveness of their products. The investors behind QUATRE LAB include Columbus Venture Partners through its Columbus Life Sciences Fund III and Gestión de Capital Riesgo del País Vasco, SGEIC, S.A. – Grupo SPRI, through its managed entities BASQUE FCR and SEED GIPUZKOA, SCR.

QUATRE LAB initiates its activities primarily focused on companies producing raw materials for Advanced Therapy Medicinal Products, new developments in Synthetic Chemistry, and Potency Assays, among others. With a team of highly qualified experts and a state-of-the-art laboratory equipped with cutting-edge technology, QUATRE LAB positions itself as a reliable partner for the pharmaceutical industry in the Basque Country.

The main services offered by QUATRE LAB include:

Quality Analysis: Comprehensive evaluation of pharmaceutical products and advanced therapies to ensure compliance with the most demanding standards (Good Manufacturing Practices).
Research and Development: Collaboration on research and development projects to improve the efficacy and safety of medicines.
Regulatory Compliance: Guidance and support in preparing the necessary regulatory documentation for drug approval.

The opening of QUATRE LAB represents a significant step forward in promoting innovation and quality in the field of advanced therapies in San Sebastián and its surroundings. The company is committed to excellence and customer satisfaction, and its inauguration marks a significant milestone in the development of the local pharmaceutical industry.

Gestión de Capital Riesgo del País Vasco is a venture capital entity management company founded in 1985 by the Basque Government through SPRI to promote and stimulate the Basque industrial fabric by temporarily participating in the equity of Basque companies. It invests primarily in innovative entrepreneurship projects, projects aligned with European RIS3 strategies, and projects that promote the internationalization, growth, and innovation of Basque companies.

Columbus Venture Partners is a Spanish venture capital management company that brings a unique approach to investing in outstanding opportunities across all stages of (bio) pharmaceutical drug development and advanced biopharmaceutical manufacturing technologies. Columbus VP manages over $250 million across its three funds and has built an impressive track record of performance with recently successful exits in Viralgen, Askbio, PTS, Sanifit, or Recovid, among others. The Columbus professional team combines solid scientific, medical, and business knowledge with extensive experience in the field of biotechnology entrepreneurship. For more information, please visit www.columbusvp.com.

Source: www.spri.eus